Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations.

The bias associated with heterogeneous populations suggests that NICE may need to be more cautious when appraising therapies and to consider model averaging or the separate modelling of subgroups when heterogeneity is suspected or detected.